FORM 8-K
Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 2, 2004 (June 2, 2004)

ENDO PHARMACEUTICALS HOLDINGS INC.


(Exact name of registrant as specified in its charter)
         
DELAWARE   001-15989   13-4022871

 
(State or other
jurisdiction of
incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)
         
100 Painters Drive
Chadds Ford, Pennsylvania
       
19317

 
(Address of principal executive offices)       (Zip Code)

(610) 558-9800


(Registrant’s telephone number, including area code)

N/A


(Former name or former address, if changed since last report)

 


TABLE OF CONTENTS

Item 7. Financial Statements and Exhibits.
Item 9. Regulation FD Disclosure.
SIGNATURES
INDEX TO EXHIBITS
SLIDE PRESENTATION


Table of Contents

Item 7. Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

     Not applicable.

(b) Pro Forma Financial Information.

     Not applicable.

(c) Exhibits.

     
Exhibit Number
  Description
99.1
  Slide Presentation of Endo Pharmaceuticals Holdings Inc. dated June 2, 2004

Item 9. Regulation FD Disclosure.

     On June 2, 2004, the Registrant intends to make a slide presentation at the FBR Growth Investor Conference in New York, New York, a copy of which presentation is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

 


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

         
  ENDO PHARMACEUTICALS HOLDINGS INC.
(Registrant)
 
 
  By:   /s/ CAROL A. AMMON    
    Name:   Carol A. Ammon   
    Title:   Chairman & Chief Executive Officer   
 

Dated: June 2, 2004

 


Table of Contents

INDEX TO EXHIBITS

     
Exhibit No.
  Description
99.1
  Slide Presentation of Endo Pharmaceuticals Holdings Inc. dated June 2, 2004